Canada

Essa Pharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

USP Workshop 2021

Participation Not Confirmed

Update your events

ESSA Pharma Inks Clinical Collaboration with Janssen to Evaluate EPI-7386 Combination in Metastatic Castration-Resistant Prostate Cancer

Lead Product(s): EPI-7386,Apalutamide

Therapeutic Area: Oncology Product Name: EPI-7386

Highest Development Status: Phase I/ Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Janssen Pharmaceutical

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration January 13, 2021

Details:

Janssen may sponsor and conduct up to two Phase 1/2 studies evaluating the combination of EPI-7386 and apalutamide as well as the combination of EPI-7386 with abiraterone acetate plus prednisone in patients with mCRPC who have failed second-generation antiandrogen therapy.

Repare Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

USP Workshop 2021

Participation Not Confirmed

Update your events

Repare Therapeutics Announces Dosing of First Patient in Phase 1/2 Clinical Trial of RP-3500

Lead Product(s): RP-3500,Talazoparib

Therapeutic Area: Oncology Product Name: RP-3500

Highest Development Status: Phase I/ Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 29, 2020

Details:

RP-3500 is a potent and selective oral small molecule inhibitor of ATR being developed for the treatment of solid tumors with selected genomic alterations.

Zymeworks

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

USP Workshop 2021

Participation Not Confirmed

Update your events

Zymeworks Announces First Patient Dosed in Phase 1b/2 Trial of ZW25

Lead Product(s): ZW25,Docetaxel,Tislelizumab

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase I/ Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 01, 2020

Details:

BeiGene has dosed the first patient in a two-arm Phase 1b/2 trial evaluating Zymeworks’ HER2-targeted bispecific antibody ZW25 in combination with chemotherapy for metastatic HER2+ breast cancer.